AZD9750

DRUG3 trials

Sponsors

AstraZeneca AB, Hibi Kazushige, AstraZeneca

Conditions

Metastatic Prostate CancerProstate Cancer

Phase 1

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

RecruitingNCT07336446

AstraZenecaProstate Cancer

Start: 2026-01-27End: 2029-01-26Target: 300Updated: 2026-06-23

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination with Other Anticancer Agents in Participants with Metastatic Prostate Cancer (ANDROMEDA)

Not yet recruitingCTIS2024-516976-14-00

AstraZeneca ABMetastatic Prostate Cancer

Target: 52Updated: 2026-03-31

Phase 2

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750as Monotherapy and in Combination with Other Anticancer Agents inParticipants with Metastatic Prostate Cancer (ANDROMEDA)

RecruitingJPRN-jRCT2031250648

Hibi KazushigeProstate Cancer

Start: 2026-02-19Target: 28Updated: 2026-05-25

Related Papers

Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA).

Journal of Clinical Oncology2026-05-28